A phase I, open-label study evaluating the safety and pharmacokinetics of trifluridine/tipiracil in patients with advanced solid tumors and varying degrees of renal impairment.

导出原文传递

翻译打印收藏纠错

作者： Muhammad Wasif,Saif ^[1] ; Carlos R,Becerra ^[2] ; Marwan G,Fakih ^[3] ; Weijing,Sun ^[4] ; Lazar,Popovic ^[5] ; Smitha,Krishnamurthi ^[6] ; Thomas J,George ^[7] ; Michelle A,Rudek ^[8] ; Dale R,Shepard ^[6] ; Jiri,Skopek ^[9] ; Vladimir,Sramek ^[10] ; Bojan,Zaric ^[11] ; Ikuo,Yamamiya ^[12] ; Karim A,Benhadji ^[12] ; Kensuke,Hamada ^[12] ; Yaohua,He ^[12] ; Lee,Rosen ^[13]

作者单位： Medical Oncology, Northwell Health Cancer Institute, 1111 Marcus Avenue, Suite 216, Lake Success, NY, 11042, USA. wsaif@northwell.edu. ^[1] Texas Oncology, Baylor University Medical Center, Dallas, TX, USA. ^[2] City of Hope Comprehensive Cancer Center, Duarte, CA, USA. ^[3] Division of Oncology, University of Kansas Medical Center, Kansas City, KS, USA. ^[4] Oncology Institute of Vojvodina, University of Novi Sad, Novi Sad, Serbia. ^[5] Cleveland Clinic, Cleveland, OH, USA. ^[6] University of Florida Health Cancer Center, Gainesville, FL, USA. ^[7] Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD, USA. ^[8] Thomayer Hospital Prague and Department of Biophysics and Informatics, First Medical Faculty, Prague, Czech Republic. ^[9] Fakultni Nemocnice u Sv. Anny v Brně, Anesteziologicko Resustitační Klinika, Brno, Czech Republic. ^[10] Institute for Pulmonary Diseases of Vojvodina, University of Novi Sad, Novi Sad, Serbia. ^[11] Taiho Oncology, Inc., Princeton, NJ, USA. ^[12] Division of Hematology-Oncology, University of California, Los Angeles, CA, USA. ^[13]

关键词 Pharmacokinetics Renal impairment Safety TAS-102 Trifluridine/tipiracil